Alector Inc. (ALEC)’s Financial Results Comparing With Kazia Therapeutics Limited (NASDAQ:KZIA)

Alector Inc. (NASDAQ:ALEC) and Kazia Therapeutics Limited (NASDAQ:KZIA) compete with each other in the Biotechnology sector. We will analyze and compare their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Alector Inc. 19 48.67 N/A -0.40 0.00
Kazia Therapeutics Limited 3 0.00 N/A -1.72 0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Alector Inc. and Kazia Therapeutics Limited.

Profitability

Table 2 shows the return on assets, net margins and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
Alector Inc. 0.00% 0% 0%
Kazia Therapeutics Limited 0.00% -56.3% -39.2%

Liquidity

Alector Inc.’s Current Ratio is 7.9 while its Quick Ratio is 7.9. On the competitive side is, Kazia Therapeutics Limited which has a 3.6 Current Ratio and a 3.6 Quick Ratio. Alector Inc. is better positioned to pay off short and long-term obligations compared to Kazia Therapeutics Limited.

Insider and Institutional Ownership

Institutional investors held 59.1% of Alector Inc. shares and 3.3% of Kazia Therapeutics Limited shares. Insiders held 8.1% of Alector Inc. shares. Competitively, Kazia Therapeutics Limited has 28.8% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Alector Inc. 6.24% 11.86% 7.1% 0% 0% 17.33%
Kazia Therapeutics Limited 4.53% 14.46% -16.99% 13.06% -42.41% 13.99%

For the past year Alector Inc.’s stock price has bigger growth than Kazia Therapeutics Limited.

Summary

Alector Inc. beats on 7 of the 7 factors Kazia Therapeutics Limited.

Kazia Therapeutics Limited, a biotechnology company, develops anti-cancer drugs. It has three technologies, which include phosphoinositide 3-kinase inhibitors, superbenzopyran, and anti-tropomyosin. The company is developing GDC-0084, a novel targeted therapy that has completed Phase I clinical trial for the treatment of glioblastoma; Cantrixil, which is in Phase I clinical trials to treat ovarian cancer; and Trilexium, a novel therapy that is in early stage pre-clinical development for the treatment of various cancer types. It has collaboration agreement with The University of York, The Children's Cancer Institute Australia, The Mater Institute in Queensland, and the University of Boston. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.